New Services Launch and Website Update

Physiomics PLC

02 October 2024

 

2 October 2024

Physiomics plc

("Physiomics" or the "Company")

New Services Launch and Website Update

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the official launch of its Biostatistics offering and expansion of its Data Science and Bioinformatics services.

Leveraging its existing expertise and capabilities across the core Modelling and Simulation service line, the Company is moving forward to expand its offering into the synergistic service areas of Biostatistics and Data Science; both of which play crucial roles in drug development.

Biostatistics:

Biostatistics is an essential component of clinical research. It plays a pivotal role in the setup, conduct and reporting of all trials, regardless of therapeutic area, ensuring studies are well designed, data is accurately collected and analysed, and the results are interpreted correctly. For example, during the design of interventional trials, biostatistics is used to calculate the optimum number of patients to be recruited and help define what data should be collected so that the effect of the therapy can be detected, balancing this against the size and cost of the trial.

The strategic rationale for Physiomics to develop the new Biostatistics services is three-fold. Firstly, the application of Modelling & Simulation and Biostatistics in drug development overlaps, with often the output of the former being a key input to the latter, allowing for natural follow-on work to be offered to clients. Secondly, biostatistics is a necessary component to the setup, conduct and reporting of any interventional clinical trial, from Phase 1 through to Phase 4, regardless of the therapeutic area. This opens a significant market for the Company, giving greater opportunity to scale. Finally, with both service lines utilising the same business model and similar expertise across mathematics and data science, this allows the Company to operate flexible staffing across service lines to meet demand and maximise utilisation.

Data Science and Bioinformatics:

Data Science and Bioinformatics have also become critical capabilities across the drug development continuum. From discovery through into the clinic, the volume and complexity of data being generated is increasing significantly, driven in part by advancements in technologies and regulatory pressures. Being able to effectively make use of this often-disparate data and derive insights from it is often where the challenge lies for drug developers. Data science and Bioinformatics tools and methodologies allow for the effective selection, curation, analysis and visualisation of this data.

The Company has already been leveraging Data Science and Bioinformatics tools and methodologies as part of its core Modelling and Simulation service line, selecting and curating data required to develop and calibrate its models. The opportunity to use these tools and models outside Modelling and Simulation has become more apparent, with the Company delivering on its first pure Data Science and Bioinformatics project earlier in the year. During this project, the Company supported the client capture and curated a wide range of publicly available data relating to novel oncology drug targets. The data was processed and then presented in a form that allowed the client to determine the optimum drug target across a variety of tissue types. Physiomics is keen to build upon this success and identify new opportunities in this space.

Launch:

As of 30 September 2024, Physiomics has officially launched its new Biostatistics offering, as well as its expanded offering in Data Science and Bioinformatics, allowing the Company to offer a more integrated offering to its clients. To coincide with this, the Company has completed an update of its website (www.physiomics.co.uk) and marketing materials to support a variety of go-to-market activities and campaigns over the coming weeks.

Dr Peter Sargent, CEO, commented: "We are delighted to have launched the new Biostatistics service line, as well as expand our Data Science and Bioinformatics Services. Not only can we now provide our clients a great breadth of services to support their drug development efforts, but these new services are an important component of the Company's growth strategy." 

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

[phone]

Hybridan LLP (Broker)

Claire Louise Noyce

[phone]

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

[phone]

Notes to Editor

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

END